Tag: AstraZeneca
-
Why AstraZeneca Investors Rejected a $400 Billion BMS Megadeal
Reports of a potential $400 billion AstraZeneca–Bristol Myers Squibb combination triggered a sharp market backlash and renewed questions about the value of Big Pharma megamergers.
-
AstraZeneca and Bristol Myers Squibb Explore a $400 Billion Pharma Megadeal
AstraZeneca and Bristol Myers Squibb have reportedly explored a potential $400 billion merger. While no deal has been announced, the discussions highlight how U.S. expansion, portfolio diversification and long-term growth are reshaping strategic priorities across the global pharmaceutical industry.
-
AstraZeneca Keeps Its $80 Billion Goal Despite a Major Trial Setback
AstraZeneca reaffirmed its $80 billion revenue ambition after reporting solid second-quarter results. Strong oncology and rare disease sales helped restore confidence following the failure of a major Wainua trial.
-
Why AstraZeneca Says Drug Development Must Move at “Chinese Speed”
AstraZeneca believes the next pharmaceutical race will be defined not only by scientific innovation, but also by development speed. As competition from Chinese biotech grows, AI could help accelerate drug development and improve efficiency.